Flavonoids reduce bleeding after closed haemorrhoidectomy – prospective randomized controlled trial

Abstract

BACKGROUND: Control over postoperative symptoms is of paramount importance in ambulatory surgery. This trial was therefore conducted to evaluate whether a micronized purified flavonoid fraction (MPFF) [Detralex®] does reduce postoperative bleeding after ambulatory performed closed haemorrhoidectomy as was reported in few trials after open haemorrhoidectomy. Phlebotropic activity, protective effect on the capillaries and the anti-inflammatory effect of this drug have been reported in several studies. METHODS: All consecutive patients with fourth and third degree haemorrhoids with skin tags in the period of two years were included in the study. They had had closed haemorrhoidectomy under spinal anaesthesia and were randomized to Detralex and Control group. Patients in Detralex group receive Detralex 500 mg (2 tablets three times daily for 5 days after the operation). All patients were asked to self-assess daily the presence of blood on defecation for the first week after the operation. RESULTS: There was statistically significant difference in duration of bleeding between groups (4.74 days of bleeding for the Control vs. 3.53 days for Detralex group, P < 0.05). No major complications – such as bleeding requiring transfusion or hospitalization, sepsis or urgent defecation – were noted in the follow-up period. There were no side effects from Detralex treatment. CONCLUSIONS: In our study we noticed less bleeding with prescribing flavonoids (Detralex) after closed haemorrhoidectomy.